Union Health Ministry mandates registration of Clinical Research Organizations under New Drugs and Clinical Trials Amendment Rules, effective 1st April, 2025
The Union Health Ministry has notified the New Drugs and Clinical Trials (Amendment) Rules, 2024 (“Amendment Rules”), introducing mandatory registration for Clinical […]
NPPA revises ceiling price of Chloroquine (150mg) tablet price to Rs. 1.33 per tablet; manufacturers directed to align pricing with ceiling price
The National Pharmaceutical Pricing Authority (“NPPA”), after reviewing the Wholesale Price Index (WPI) at 0.00551% for the year 2024, has revised the […]
Enhanced fines and reduced imprisonment for violations under Pharmacy Act 1948 effective 31st December, 2024: Health Ministry confirms implementation date for amendments under Jan Vishwas Act
The Ministry of Health and Family Welfare has appointed 31st December, 2024 as the date on which the amendments pertaining to the […]
Ministry of Health and Family Welfare prohibits the manufacture, sale, and distribution of S(+) Etodolac and Paracetamol Combination over safety concerns
The Health Ministry has prohibited the manufacture, sale, and distribution of the fixed-dose combination of S (+) Etodolac and Paracetamol for human […]
Health Ministry restricts the manufacture, sale or distribution of two Fixed Dose Combinations of Naproxen subject to certain conditions
The Ministry of Health and Family Welfare (“MoHFW”) has implemented restriction on the manufacture, sale or distribution of the following Fixed Dose […]
Health Ministry permits import of drugs through Cochin and Thiruvananthapuram airports
The Ministry of Health and Family Welfare (“MoHFW”) has notified the Drugs (Third Amendment) Rules, 2024. The changes in the final Notification […]
Department of Pharmaceuticals mandates self-declaration for compliance with new Uniform Code for Pharmaceutical Marketing Practices (UCPMP) by 30th June, 2024
The Department of Pharmaceuticals has directed pharmaceutical companies to submit self-declaration of adherence to the Uniform Code for Pharmaceutical Marketing Practices 2024 […]
Stakeholders in medical devices sector urged by CDSCO to ensure timely payment of retention fees to maintain validity of licenses and certificates
The Central Drugs Standard Control Organisation (“CDSCO”) has reiterated that licenses for manufacturing or importing medical devices, as well as registration certificates […]
CDSCO allows operational continuity for importers and manufacturers of Class C & D Medical Devices; pending pre-September 2023 licensing applications deemed valid until 16th August, 2024 or CLA decision
The Central Drugs Standard Control Organization (CDSCO) has issued a Circular in response to representations from various associations and stakeholders to ensure […]
NOC for manufacture of unapproved/approved new drugs/banned drugs (solely for export) to be obtained from Zonal offices via Sugam Portal, effective from 15th May 2024: CDSCO
The Central Drugs Control Standards Organization (CDSCO) has communicated to drug controllers of all States and Union Territories regarding the withdrawal of […]
Public comments invited till 25th April, 2024 on draft of revised guidance for industry to align with the New Drugs and Clinical Trials (NDCT) Rules, 2019 and Sugam application process (Version 1.2)
With a view to align the submission procedure of clinical trial application (as prescribed under the New Drugs and Clinical Trial Rules, […]
Health Ministry sets 31st December, 2024 as implementation date for Jan Vishwas Act amendments to Drugs and Cosmetics Act, 1940; drug manufacturers may be subject to increased fines for utilizing government analysts’ reports in advertisements
Pursuant to the Update reported earlier on Jan Vishwas (Amendment of Provisions) Act 2023 (please refer to e-mails in trail for details), […]